PODCAST

Cardiology

ReachMD

science & medicine medicine

All Episodes

00:00:00

Expert Perspectives on Nonsteroidal MRAs and...

Cardiology ·

2025/06/20

Guest: Muthiah Vaduganathan, MD, MPH Guest: Anuradha Lala-Trindade, MD Guest: Brendon Neuen, MBBS, PhD Heart failure with mildly reduced ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) represent a significant and growing burden for patients and the healthcare system, not only in cardiovascular medicine, but also in the context of cardio-kidney-metabolic (CKM) syndrome. Trials are underway evaluating new therapies that may offer benefits to patients with

00:00:00

Shifting Treatment Paradigm in HFmrEF/HFpEF:...

Cardiology ·

2025/05/30

Guest: Faiez Zannad, MD, PhD Guest: John McMurray, MD Join Drs. John McMurray and Faiez Zannad as they explore the evolving role of MRAs in heart failure management. From RALES and TOPCAT to the recent FINEARTS-HF trial, they highlight key findings that shape how steroidal and nonsteroidal MRAs are used in clinical practice. Discover how the nonsteroidal MRA finerenone is expanding treatment options for patients with HFmrEF and HFpEF.

00:00:00

Masterclass in Cardiac Amyloidosis: Disease Spectrum,...

Cardiology ·

2025/01/24

Host: Saurabh Malhotra, MD, MPH Guest: Kevin Alexander, MD Guest: Tawfiq Al-lahham, MD Guest: Sarah Cuddy, MD Guest: Angela Dispenzieri, MD Guest: Anita D’Souza, MD Guest: Foluso Fakorede, MD Guest: Mazen Hanna, MD Guest: Isabelle Lousada Guest: Ahmad Masri, MD, MS Guest: Mathew S. Maurer, MD Guest: Matthew Parker, MD Guest: Frederick Ruberg, MD Guest: Andrew Staron, MD Guest: Prem Soman, MD, PhD Guest: Jonathan Wall, PhD Guest:

00:00:00

Cardiorenal Collaboration: Optimizing...

Cardiology ·

2024/10/23

Host: Raymond Townsend, MD Guest: Melissa Magwire, RN, MSN, CDE Guest: Michael Weber, MD The outcomes of large clinical trials such as EMPA-REG have demonstrated that SGLT2 inhibitors are effective, but they do more than lower blood sugar and improve A1c. Similar to statins a long time ago, SGLT2 inhibitors offer many advantages for patients with potential atherosclerotic endpoints. Learn from our expert multidisciplinary panel as they explore the various approaches to

00:00:00

New Horizons: Unraveling Novel Therapies for Enhanced...

Cardiology ·

2024/10/18

Host: Carolyn S. P. Lam, MBBS, PhD, MRCP, MS, FACC, FAMS, FESC Guest: Scott Solomon, MD Guest: Mikhail Kosiborod, MD There are limited therapeutic options for patients with heart failure with mid-range or preserved ejection fraction (HFmrEF/HFpEF). Recently, new data were released on the efficacy and safety of nonsteroidal mineralocorticoid receptor antagonists (MRAs) in patients with HFmrEF/HFpEF. What are the outcomes of the FINEARTS-HF trial with finerenone in this patient

00:00:00

Strategic Excellence: Mastering the Expanding ATTR-CM...

Cardiology ·

2024/05/22

Host: Hongya Chen, PharmD Guest: Jennifer Day, PharmD Guest: Keith C. Ferdinand, MD, FACC, FAHA, FASPC, FNLA Join us in this educational endeavor to empower pharmacists with the latest insights and strategies for improved decision-making in ATTR-CM management. The program emphasizes the latest clinical insights in this evolving therapeutic landscape, addressing changes in diagnostic approaches over the last decade, and providing a nuanced perspective on ATTR-CM progression for

00:00:00

ATTR-CM Management: Pearls From Recent Clinical...

Cardiology ·

2024/05/09

Host: Marianna Fontana, MD Guest: Ronald Witteles, MD Struggling to manage ATTR-CM? Our faculty are exploring the key considerations shaping current clinical trial design and how innovations might change our approach to the management of ATTR-CM in the future. They'll also discuss the use of outpatient diuretic intensification as a potential endpoint in trials and the ongoing challenge of defining and measuring “clinically meaningful benefit” for patients with ATTR-CM. Don't miss

00:00:00

Right from the Onset: PE Diagnosis, Management

Cardiology ·

2024/03/29

Host: Bruce L. Davidson, MD, MPH Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects

00:00:00

Risk Assessment: Who’s Most Susceptible for a...

Cardiology ·

2024/03/29

Host: Scott Kaatz, DO, MSc, FACP, SFHM Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights

00:00:00

VTE Prophylaxis in Patients at Risk for a Secondary...

Cardiology ·

2024/03/29

00:00:00

Mrs. V.T. Elizabeth: A Case Study on the Secondary...

Cardiology ·

2024/03/29

Host: Deborah Siegal, MD, MSc, FRCPC Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights

00:00:00

How Do We Effectively Integrate the Latest VTE...

Cardiology ·

2024/03/29

00:00:00

What Is the Acute and Post Acute Risk of VTE in Acute...

Cardiology ·

2024/03/29

Host: Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also

00:00:00

Putting It All Together: Coordinating the...

Cardiology ·

2024/03/29

Host: Bruce L. Davidson, MD, MPH Host: Victor F. Tapson, MD Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This

00:00:00

Case Time! VTE Prophylaxis Post Hip Replacement

Cardiology ·

2024/03/29

Host: Victor F. Tapson, MD Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights aspects of the

00:00:00

Right from the Onset: DVT Diagnosis, Management

Cardiology ·

2024/03/29

00:00:00

What Do the Guidelines Suggest for Prophylaxis, and...

Cardiology ·

2024/03/29

Host: Alfonso J. Tafur, MD, MS, MBA, RPVI Host: Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and

00:00:00

Case Time! V.T. Edwards: Management of Extended...

Cardiology ·

2024/03/29

00:00:00

What Options Are Available Prophylactically for My...

Cardiology ·

2024/03/29

Host: Alfonso J. Tafur, MD, MS, MBA, RPVI Venous thromboembolism (VTE) morbidity, mortality, and impact on the overall quality of life start with timely diagnosis, appropriate initial treatment, and management. Prevention occurs at a primary and secondary level. This program focuses on all the components to manage VTEs at all of these levels to help clinicians effectively manage their patients and reduce preventable harm and corresponding healthcare costs. This program also highlights

00:00:00

CARE HK in HF: Designing a Real-world Study to...

Cardiology ·

2020/10/05

Host: Mikhail Kosiborod, MD Despite evidence and guideline recommendations, renin-angiotensin-aldosterone system inhibitor (RAASi) therapy tends to be used suboptimally among patients with heart failure (HF), particularly in patients with chronic kidney disease (CKD). What are the real-world factors that influence RAASi treatment decisions in patients with HF who have or are at risk for hyperkalemia? Hear about how the CARE HK in HF study is being designed to explore the real-world

20 results

Cardiology

All Episodes

Similar Podcasts

Eye On The Sky

Vermont Public

Cienciaes.com

cienciaes.com

This Week in Virology

Vincent Racaniello

Hablando con Científicos - Cienciaes.com

cienciaes.com

The Elective Rotation: A Critical Care Hospital Pharmacy Podcast

Pharmacy Joe